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Abstract
Prion diseases are fatal neurodegenerative disorders characterized by a long pre-symptomatic phase followed by rapid and
progressive clinical phase. Although rare in humans, the unconventional infectious nature of the disease raises the potential for
an epidemic. Unfortunately, no treatment is currently available. The hallmark event in prion diseases is the accumulation of a
misfolded and infectious form of the prion protein (PrP
Sc). Previous reports have shown that PrP
Sc induces endoplasmic
reticulum stress and changes in calcium homeostasis in the brain of affected individuals. In this study we show that the calcium-
dependentphosphataseCalcineurin(CaN)ishyperactivatedbothinvitroandinvivoasaresultofPrP
Scformation.CaNactivation
mediatesprion-inducedneurodegeneration,suggestingthatinhibitionofthisphosphatasecouldbeatargetfortherapy.Totest
thishypothesis,prioninfectedwildtypemiceweretreatedintra-peritoneallywiththeCaNinhibitorFK506attheclinicalphaseof
the disease. Treated animals exhibited reduced severity of the clinical abnormalities and increased survival time compared to
vehicletreatedcontrols.TreatmentalsoledtoasignificantincreaseinthebrainlevelsoftheCaNdownstreamtargetspCREBand
pBAD, which paralleled the decrease of CaN activity. Importantly, we observed a lower degree of neurodegeneration in animals
treated with the drug as revealed by a higher number of neurons and a lower quantity of degenerating nerve cells. These
changes were not dependent on PrP
Sc formation, since the protein accumulated in the brain to the same levels as in the
untreated mice. Our findings contribute to an understanding of the mechanism of neurodegeneration in prion diseases and
more importantly may provide a novel strategy for therapy that is beneficial at the clinical phase of the disease.
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Introduction
Prion diseases or transmissible spongiform encephalopathies (TSEs)
are neurodegenerative disorders affecting humans and animals alike,
which are characterized by the presence of PrP
Sc,a na b n o r m a l ,
protease-resistant isoform of the cellular prion protein, called PrP
C [1].
The most common TSE in humans is Creutzfeldt-Jakob disease (CJD)
affecting on average one new patient per million people each year [2].
I na n i m a l st h em o s tc o m m o nT S Ei ss c r a p i e ,w h i c hi sa ne n d e m i c
disease affecting sheep and goats for centuries. However, it is the recent
appearance of new TSEs that have put prions in the spotlight. These
new diseases include variant CJD (vCJD) in humans, bovine
spongiform encephalopathy (BSE) in cattle and chronic wasting
disease (CWD) in elk and deer. vCJD is the newest and most
frightening member of the TSE group. Its appearance in 1996 has
been undoubtedly linked to the BSE outbreak and despite that the
number of new cases of vCJD seems to be decreasing, there is an
enormous concern of secondary transmission of vCJD among humans
[3–5]. Indeed, recent reports have indicated the propagation of the
disease through blood transfusion [6,7].
At this time there is no effective treatment or cure for TSE [8,9].
The disease is inevitably fatal and affected people usually die
within months of the appearance of the first clinical symptoms.
Assuming that the hallmark event in the disease is the conversion
of PrP
C into PrP
Sc, a reasonable therapeutic target would be to
prevent PrP misfolding and prion replication. This approach has
been extensively attempted by many research groups and some
compounds have been identified with the capability to decrease
prion replication and delay the onset of the clinical disease
[1,9,10]. However, these compounds produce benefit only when
they are administered during the pre-symptomatic stage of the
disease, long before the appearance of clinical symptoms. It is
likely that compounds interfering with prion replication would
have little or no benefit to patients with already established clinical
disease, since at the time clinical symptoms appear there is
substantial brain damage. It seems that a treatment aimed at
patients with established symptoms of CJD would need to attack
the cellular pathways implicated in brain damage. This is precisely
the major goal of this study, which comes from our recent studies
of the mechanism of neurodegeneration in prion diseases.
PLoS Pathogens | www.plospathogens.org 1 October 2010 | Volume 6 | Issue 10 | e1001138We have previously shown that purified PrP
Sc from scrapie-
infected brains is able to induce cell death in primary neuron
cultures [11]. Our studies demonstrated that the cellular pathway
controlling the induction of apoptosis involves stress of the
endoplasmic reticulum (ER) [11]. The first alteration observed
when cells were exposed to PrP
Sc consisted of the sustained release
of calcium from the ER followed by the induction of the unfolded
protein response (UPR). The UPR consists of the up-regulation of
several molecular chaperones and clearance mechanism to
attempt correcting the protein misfolding problem [12]. In
support of these in vitro observations, histological and biochemical
analysis of brains from scrapie-sick mice and from humans affected
by sCJD and vCJD demonstrated the presence of activated
caspases and the induction of ER-stress inducible chaperones in
brain areas exhibiting extensive neuronal death [11,13,14]. In the
present study we show that an additional consequence of calcium
release from the stressed ER is the hyperactivation in vitro and in
vivo of a key protein, termed calcineurin (CaN). CaN is a
phosphatase of type 2B highly abundant in the brain that has been
implicated in the regulation of synaptic plasticity, memory and
neuronal death [15]. CaN immunoreactivity is observed exclu-
sively in neurons in various brain regions, but not in glial cells,
including astrocytes, oligodendrocytes, microglia and ependymal
cells both in humans and rodents [16,17]. Subcellular localization
studies by electron microscopy showed that calcineurin was found
in dendrites including postsynaptic densities, cell bodies, spines,
axons and terminals [16]. The activity of this enzyme is regulated
by the Ca
2+-calmodulin complex. Optimum activity of CaN is
required to maintain the proper phosphorylation state of different
important targets, like apoptosis inducer BAD or transcription
factor CREB. Hyper-activation of CaN reduces the phosphory-
lation of BAD [18], which then disassociate from the scaffolding
protein 14-3-3 and interacts with Bcl-Lx or other Bcl2 family
proteins located in the mitochondrial membrane. As a result
cytochrome C is released in the cytoplasm, leading to caspase
activation and finally causing apoptosis. On the other hand
dephosphorylated by hyper-activated CaN, CREB is not able to
translocate into the nucleus to act as a transcription factor to
regulate expression of different genes required for synaptic
plasticity [19].
To study the potential role of CaN in prion-induced
neurodegeneration and to assess the possibility of inhibiting this
phosphatase as a putative target for therapeutic intervention, we
treated prion infected animals with the FDA-approved CaN
inhibitor FK506. FK506 (also known as Tacrolimus and Prograf)
is a natural product produced by the fungus Streptomyces
tsukubaensis, marketed to prevent transplant rejection [20]. By
inhibiting CaN, the drug suppresses both humoral and cellular
immune responses [21]. Our results show that mice receiving
FK506 after the onset of the clinical phase of prion disease
exhibited improved motor activity and coordination, lived longer
and had a decreased level of brain degeneration when compared
to untreated prion infected animals. These findings suggest that
inhibition of CaN activity in the brain may be a promising new
approach for the treatment of prion diseases.
Results
PrP
Sc-induced neurodegeneration is mediated by CaN
activation in vitro and in vivo
Our previous results showed that PrP
Sc accumulation induced
ER stress [11]. One of the alterations produced by ER stress is the
change of calcium homeostasis. Indeed, exposure of N2A mouse
neuroblastoma cells to brain-isolated PrP
Sc results in the increase
of cytoplasmatic calcium (Fig. 1A), which as shown before is
coming from the ER [11]. It is well-established that CaN activity is
modulated by cytoplasmic calcium concentration. To assess
whether neuroblastoma cells exposed to PrP
Sc indeed have a
higher level of CaN activity, we measured the phosphatase activity
in N2A cells treated with 200 nM of PrP
Sc. The results show that
CaN activity is significantly elevated in cells exposed to PrP
Sc, but
not to the same concentration of the natively folded recombinant
prion protein (PrP
C) (Fig. 1B). As positive control we used
Thapsigargin, an inhibitor of the sarco/endoplasmic reticulum
Ca
2+ ATPase that increases cytoplasmatic calcium concentration
[22]. FK506 (also known as Tacrolimus and Prograf) is a FDA
approved drug able to inhibit CaN activity [21]. The PrP
Sc-
induced elevation of CaN activity was efficiently blocked by
concomitant addition of FK506 (Fig. 1B).
To assess the effect of PrP
Sc and subsequent CaN activation in
cell damage, we measured cell death by release of lactate
dehydrogenase (LDH) and cell viability by the MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in
N2A cells exposed to 200 nM of PrP
Sc in the presence or absence
of FK506 (Fig. 1C). Cell death produced by treatment with PrP
Sc
or thapsigargin was significantly decreased by addition of the CaN
inhibitor FK506 (Fig 1C, left panel). Indeed, the rate of
neuroblastoma cell death after treatment with PrP
Sc and FK506
was not significantly different from the control untreated cells,
indicating that FK506 completely protected cells from PrP
Sc toxic
activity. A similar protective effect of FK506 against PrP
Sc
neurotoxicity was found when cell viability was measured by
MTT reduction (Fig. 1C, right panel). Treatment of cells with
FK506 in the absence of PrP
Sc did not change cell death or
viability (data not shown).
To study whether the increase in CaN activity observed in vitro
as a consequence of PrP
Sc formation also occurs under in vivo
conditions, we measured CaN activity in brain of animals infected
with prions. Groups of mice intra-peritoneally infected with the
RML prion strain were sacrificed at various time points until the
onset of the clinical signs, which under these conditions occurred
between 210 and 230 days post-inoculation. A basal CaN activity
in brain was detected at all time points during the pre-
symptomatic phase, which was not different from the activity
found in non-inoculated animals (Fig. 1D). However, at the
beginning of the clinical phase of the disease, a ,3-fold higher
Author Summary
Prion diseases are a group of infectious neurodegenerative
disorders producing a rapid and devastating clinical
deterioration. The disease is 100% fatal and affected
patients usually die within one year from the appearance
of the first clinical alterations. Currently there is no
treatment available for these diseases. The main goal of
this study was to show that inhibition of the brain
phophatase calcineurin is a therapeutic target for prion
diseases. We show that calcineurin is hyperactivated as a
consequence of endoplasmic reticulum stress produced by
accumulation of misfolded prion protein. Treatment of
animals showing the symptoms of prion disease with the
calcineurin inhibitor FK506 resulted in a substantial
decrease in the severity of clinical signs, an increase in
animal survival and a reduction in brain degeneration.
These findings indicate that calcineurin might play an
important role in prion-induced neurodegeneration and
inhibition of this phosphatase might represent a promising
novel approach for prion disease therapy.
Calcineurin Inhibition for Prion Disease Therapy
PLoS Pathogens | www.plospathogens.org 2 October 2010 | Volume 6 | Issue 10 | e1001138Figure 1. PrP
Sc neurotoxicity is mediated by CaN activation. Panels A, B and C show the results of in vitro experiments in which 200 nM of
purified PrP
Sc was added to the medium of 1610
5 N2A neuroblastoma cells. A, Calcium concentration in cytoplasm was measured after 20 minutes
of exposure to PrP
Sc using the Fluo-4 Direct Calcium Assay kit in 96 well plate according to manufacturer’s protocol. B, Cells were treated for 36 h
with 200nM PrP
Sc in the presence or the absence of 10mM FK506. As controls, cells were treated with 200 nM of purified recombinant PrP
C or with
20mM Thapsigargin (with or without 10 mM FK506). CaN activity was measured using the Calcineurin Cellular Activity Assay kit from Calbiochem
according to manufacturer’s protocol. C, The effect of PrP
Sc on cell death (left panel) or cell viability (right panel) was measured after 48 hours of
incubation (except for the experiment with Thapsigargin that was measured 24 hours after addition of the chemicals). The LDH and MTT assay were
performed using the LDH assay kit (Promega) and Cell proliferation assay kit (Roche), respectively, according to the manufacturers’ protocol. In case
of the cell death assay the positive control, which represents the maximum amount of LDH release, was done by addition of a final concentration of
2% tween20 to the culture medium. All experiments in panels A, C and C were done in triplicate and the values correspond to the average 6
standard error. In these experiments the data was analyzed by one-way ANOVA, followed by the Tukey’s Multiple Comparison post-test to estimate
the significance of the differences. D, To study the potential role of CaN in prion diseases we measured the level of CaN activity in animals at different
stages of prion disease. For this purpose, groups of 3 mice were sacrificed at different times after i.p. inoculation with RML prions. The brain was
collected, homogenized and the CaN activity measured as described in Methods. CaN activity is expressed as a percentage of the value obtained in
non-infected wild type mice. There were not differences in CaN activity in the brain of control (non-infected) animals during the age range studied
(150–250 days). The values used for normalization corresponded to an average of all the animals tested. The differences were analyzed by unpaired
student t-test. * P,0.05; ** P,0.01; *** P,0.001.
doi:10.1371/journal.ppat.1001138.g001
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phosphatase is significantly elevated at the time brain damage and
clinical disease occur.
Inhibition of CaN activity decreases disease severity and
increases animal survival
To study whether CaN activity is implicated in the progression of
prion disease and whether the inhibition of this phosphatase could
be a good target for therapy, groups of mice were treated with
FK506 during the clinical phase of the disease. Clinical onset of the
disease was carefully measured every other week by two different
researchers monitoring the appearance of hunch and trail rigidity,
which is the first alteration clearly associated to the disease. When
the clinical symptoms were unambiguously observed during 3
consecutive days, infected mice were injected i.p. daily with 5 mg/
kg of FK506 (dissolved in saline, containing 1.25% PEG40 Castor
oil and 2% ethanol) (n=14) or with vehicle (n=14). This dose was
chosen based on a toxicology study showing that administration of
FK506 at concentrations higher than 10 mg/Kg produced side-
effects detectable by behavioral tests (data not shown). As a control
we used another immunosuppressant drug, Rapamycin (n=8),
which does not interfere with CaN activity. Treatments lasted until
animals died or were sacrificed for analysis.
Progressive decline in motor coordination and activity is a well
documented clinical feature of prion disease [23], which likely is
the result of loss of synaptic integrity. Therefore motor alterations
during the clinical phase of the disease in animals treated with
FK506, rapamycin or vehicle were assessed by using rota-rod
(Fig 2A) and open field tests (Fig 2B). The motor coordination in
the rota-rod test was measured once a week in a 3 min time
interval and was expressed as a percentage of the activity at day 0
(day in which treatment was started). The results showed that
prion infected animals treated with vehicle or rapamycin
experienced a progressive and significant decline on motor
coordination, whereas animals treated with FK506 showed no
significant decrease on performance over de 5 weeks period
(Fig. 2A). Indeed, the rota-rod performance of the FK506
treatment group was similar to that of non-infected animals
(either treated or untreated with FK506), used as control. The
slight increase on performance over the time period in control
animals probably reflects that animals become more familiarized
with the test. The locomotor ability in open field test was measured
at day 21 after starting the treatment, by the rearing activity
during 20s and corresponds to the time animals spent only on the
hind limb. As shown in figure 2B, the rearing activity in prion
infected animals was dramatically reduced compared to control
non-inoculated animals. Treatment with FK506, but not rapamy-
cin, prevented significantly the locomotor deficiencies (Fig. 2B).
Next we investigated the survival time of the animals under
treatment. Infected mice were left to die naturally and time of
death was recorded. Figure 3 shows the survival curve of the group
treated with FK506 (n=10, red line), treated with rapamycin
(n=4, blue line) or the vehicle group (n=10, black line). The
results showed a 35% increase in survival of the group treated with
CaN inhibitor compared to the vehicle treated control (P=0.039,
as estimated by the Log-rank Mantel-cox test).
FK506 treatment does not alter PrP
Sc accumulation, but
increases pCREB and pBAD
To study the effect of FK506 treatment on neurodegeneration,
4 random animals from each treatment group were sacrificed at
the time in which the first mice injected with vehicle reached the
stage 5 of the clinical disease (around 20 days after the beginning
of the treatment), their brain collected and one hemisphere was
kept frozen and the other fixed for histological analysis (see below).
Frozen brains were homogenized in TBS with protease inhibitors.
The level of CaN activity in total brain was measured as described
in Methods. Prion inoculated mice had substantially higher CaN
Figure 2. Inhibition of CaN decreases severity of disease clinical
alterations. Animals were treated daily with 5 mg/Kg of FK506,
rapamycin or vehicle (the buffer used to dissolve FK506) starting at the
time they exhibited the first signs of prion disease. Behavioral and motor
alterations were measured over time by Rota-rod (A) or open field (B)
tests and compared with age matched wild type animals treated with
FK506. Activity was assessed once a week and the initial performance
(t=0) was normalized with respect to the age matched wild type non-
infected animals. The locomotor activity in the rota-rod test was
measured by placing mice on the rotating rod with an accelerated
speed and the total time spent without falling was recorded. The rearing
activity in the open field box was measured as the number of times the
animal spent in vertical activity during 20s intervals. The graph in panel B
shows the results obtained at 21 days after beginning of the treatment.
Each value corresponds to the average and standard error (n=4 for
rapamycin and n=10 for other groups).
doi:10.1371/journal.ppat.1001138.g002
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the result shown in Fig 1D. The levels of CaN activity in prion
inoculated mice were normalized upon treatment with FK506,
indicating that the drug is acting as expected in the brain and that
the dose used was appropriate.
To measure PrP
Sc accumulation in the different group of
animals, samples were treated with PK (50 mg/ml for 1h at 37uC)
and 1/5 and 1/25 dilutions from the 10% brain homogenate were
evaluated by western blot. The result shows that FK506 treatment
did not alter PrP
Sc accumulation (Fig. 4B), a result consistent with
our hypothesis that CaN activation is a downstream event of prion
replication. To study the influence of CaN inhibition in the
phosphorylation stage of some of the key substrates of the
phosphatase involved in controlling synaptic plasticity and
neuronal apoptosis, we measured the brain levels of pCREB,
pBAD as well as total CREB and BAD. The western blot in
figure 4C shows the results for CREB of two representative
animals per group and the graph in the right panel represents the
quantification of the ratio pCREB/total CREB. The results
indicate that scrapie-affected mice receiving vehicle have a 2-fold
reduction of pCREB (normalized to total CREB) compared to
non-infected animals. Strikingly, treatment with FK506, but not
rapamycin, restored the concentration of this phosphorylated
transcription factor to reach levels indistinguishable from healthy
controls (Fig. 4C). A similar result was observed when the pro-
apoptotic BAD protein was analyzed. Indeed, prion affected mice
have a 3–4 fold reduction of pBAD/total BAD ratio compared to
controls. Again, the phosphorylation state of this important protein
was restored upon treatment with FK506 (Fig. 4D).
CaN inhibition reduces neurodegeneration in prion
affected mice
To further assess the effect of FK506 treatment on prion
induced neurodegeneration, fixed brains from 4 animals per group
were stained and analyzed. The histopathological alterations
observed in prion affected animals, include spongiform degener-
ation, astroglyosis, neuronal death and synaptic dysfunction.
Analysis of the extent of vacuolation revealed no significant
differences between treated and un-treated animals (Figure S1).
Although, spongiosis is the most characteristic brain alterations
observed in TSEs, its role in brain dysfunction and clinical disease
is mostly unclear [24,25]. Brain inflammatory changes in the form
of reactive astrocytes and activated microglia are also a typical
alteration associated to prion diseases [26]. Since CaN has been
implicated in immunological and inflammatory pathways [27], we
wanted to analyze in detail the effect of FK506 treatment on the
extent of astrocytosis and microglial alteration. Astrogliosis was
studied by staining the tissue with the anti-GFAP (Glial fibrillary
acidic protein) antibody and reactive microglia with the anti-AIF1
(allograph inflammatory factor 1) antibody (Fig. 5A). Quantifica-
tion of the area of the thalamus containing reactive astrocytes
(Fig. 5B) and activated microglia (Fig. 5B) revealed a pronounced
difference between samples coming from non-infected and prion
infected animals. However, no statistically significant differences
on the extent of brain inflammation were observed among prion
infected animals treated or untreated with FK506 or rapamycin.
These results suggest that the therapeutic effect of FK506 is not
mediated by a neuroimmune pathway.
To study the number of neurons present in the brain, we stained
tissue slides with NeuN, a specific and well-established neuronal
marker [28]. The data shows a substantially higher quantity of
neurons in the thalamus of FK506 treated-mice, compared with
prion affected animals treated with vehicle or rapamycin (Fig. 6).
Indeed, mice treated with the CaN inhibitor have almost twice the
number of neurons as their untreated-mates. However, still the
treated animals have around 50% less neurons than normal animals
not affected by prion diseases (Fig. 6), indicating that the treatment
only stop in part the neurodegeneration process. In order to further
study the influence of the treatment on neuronal damage, we stained
the tissue with Fluoro-Jade, a well-established method to detect
Figure 3. Increase in survival of prion infected animals by treatment with CaN inhibitor. Animals were treated daily with 5 mg/Kg of
FK506, rapamycin or vehicle (the buffer used to dissolve FK506 and rapamycin) starting at the time they exhibited the first signs of prion disease.
Groups of animals were left to die to determine survival time in each condition. FK506 treated mice (n=10, red line; average symptomatic phase:
3562.8 days), treated with rapamycin (n=4, blue line; average symptomatic phase: 20.960.9 days), vehicle group (n=10, black line; average
symptomatic phase: 26.262.2 days). Differences were analyzed by the Log-rank (Matel-cox) test.
doi:10.1371/journal.ppat.1001138.g003
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treated with FK506 has a substantially lower level of Fluoro-Jade
stained cells as compared with animals treated with vehicle or
rapamycin. Again, the effect of the treatment was not complete, since
FK506 treated mice still have significantly more degenerating
neurons than control non-infected animals (Fig. 7).
Discussion
TSEs are dreadful diseases that produce a 100% fatality rate
and a progressive and rapid deterioration which leads to complete
disability. Currently, there is no therapy available against prion
disorders [1]. The self-propagating protein misfolding process that
features prion diseases amplifies the toxic and infectious prion in a
logarithmic scale making it difficult for development of an efficient
therapy at the symptomatic phase. Since there still not available a
test to diagnose prion disease at the pre-symptomatic stage [30],
the top priority is to develop strategies that could be beneficial
after the patients show the first clinical signs of the disease.
Considering that a central event in TSEs is the conversion of
PrP
C into PrP
Sc, a widely pursued therapeutic strategy has been to
disrupt PrP
Sc formation. This approach has been extensively
Figure 4. Effect of FK506 treatment on PrP
Sc formation, CaN activity and downstream targets. To study the effect of the treatment on
neurodegeneration, 4 random animals from each treatment group were sacrificed when mice injected with vehicle reached the stage 5 of the clinical
disease. Their brain was collected and one hemisphere was kept frozen for biochemical studies. As controls we used age-matched non-infected
animals that received either vehicle or FK506. A, levels of CaN activity were measured as described in Methods. The values represent the average 6
standard error of 3 determinations. B, PrP
Sc accumulation was determined by western blot after PK digestion as described in Methods. For each
condition, the western blot of a representative animal is shown in two dilutions (5 and 25 fold dilution of 10% brain homogenate). Normal mouse
brain homogenate treated in the same way with or without PK digestion was also loaded. C, The brain levels of pCREB and total CREB were
determined by western blots in animals infected with prions and treated with vehicle, FK506 or rapamycin, as well as in non-infected age-matched
mice treated with vehicle or with FK506. The blot shows the results of 2 different animals per group and the graph in the right side display the
densitometric analysis of the 4 animals studied in each condition. The values correspond to the average 6 standard error. D, The levels of pBAD and
total BAD were estimated by Western blot and the data densitometrically analyzed. As before, the values in the graph correspond to the average 6
standard error of 4 animals per group. For the western blot analysis, the same total protein concentration was loaded in each lane and equal loading
was additionally confirmed by developing the membrane with anti-actin antibody. The data was statistically analyzed by One-way ANOVA followed
by the Tukey’s Multiple comparison post-test. * P,0.05; ** P,0.01; *** P,0.001.
doi:10.1371/journal.ppat.1001138.g004
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identified with activity in vitro and in vivo. The list of compounds
studied include: Polyanionic molecules, dextran sulphate, pentosan
polysulphate, heparin sulphate mimetics, Phosphorothioate oligo-
nucleotides, congo red analogs, suramin, curcumin, quinacrine,
dendritic polyamines, tetracycline, amphotericin B, beta-sheet
breaker peptides, anti-PrP antibodies, etc (for reviews, see
[8,9,31]). However, these compounds produce a benefit mostly
when they are administered during the pre-symptomatic stage of
the disease, long before the appearance of clinical symptoms.
Despite of the lack of positive results in animal models at the
clinical phase of the disease, the unmet need for a medicine to treat
patients resulted in human clinical trials with at least 3 of these
drugs: quinacrine, amphotericin B and pentosan polysulphate [9].
Quinacrine, chlorpromazine, and some of their tricyclic deriva-
tives were described as efficient inhibitors of PrP
Sc formation in
murine neuroblastoma cells chronically infected with scrapie
[32,33]. However, subsequent animal experiments failed to
demonstrate efficacy in the treatment of TSEs [34], even after
intraventricular infusion [35]. Because quinacrine and chlorprom-
azine have been used in human medicine as anti-malarial and
anti-psychotic drugs, respectively, they were tested in small clinical
trials. No therapeutic effect was seen following quinacrine
treatment in two independent trials, although some transient
improvement occasionally occurred [36,37]. Amphothericin B and
some of its analogues inhibited prion replication in infected cell
cultures [38] and delayed the appearance of spongiosis, astro-
gliosis, and PrP
Sc accumulation in the brain of scrapie-infected
hamsters [39,40]. However, an attempt to treat a CJD patient with
amphothericin B was unsuccessful [41]. In view of its high systemic
toxicity, these results decrease hopes that amphothericin B will
prove useful in prion disease therapy. Several in vitro and in vivo
studies have suggested pentosan polysulphate may be useful in
prion diseases [35,42–44]. Pentosan polysulphate is marketed in
some countries as a treatment for interstitial cystitis and as
anticoagulant, although its side effects include hemorrhage and
hypersensitivity reactions. The main problem for using this drug
for TSEs is that it does not cross the blood-brain barrier, so it has
Figure 5. Treatment with FK506 does not alter the extent of astrocytosis or microglial activation. The level of astrocytosis and microglial
activation in various brain areas of mice infected or non-infected with prions and subjected to diverse treatments was evaluated by histological
analysis. A, representative pictures of the thalamus region after staining with GFAP (top) and AIB-1(bottom) to stain reactive astrocytes and activated
microglia, respectively. We focused on thalamus, because this is one of the brain areas most severely affected in RML-affected animals. To
quantitatively assess the extent of astrocytosis (B) and microglial activation (C) six sections of thalamus were analyzed using the image analysis
program Image J from NIH. The values correspond to the stained area expressed as a percentage of the total tissue area. Each value corresponds to
the average and standard error (n=3 for rapamycin group, and n=4 for all other groups). The data was statistically analyzed by One-way ANOVA
followed by the Tukey’s Multiple comparison post-test. *** P,0.001.
doi:10.1371/journal.ppat.1001138.g005
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replication phase) or directly into the brain. Several small
observational trials by intra-cerebroventricular infusion of pento-
san polysulphate have been conducted, some of them showing
promising results [45–48]. However, the fact that the drug has to
be administered directly into the brain makes its routine use very
complicated.
Our approach provides a novel molecular target down-stream
of the prion misfolding process and aims to prevent the signaling
pathways leading to synaptic alterations and neuronal death.
Our data suggests that the pathway by which PrP
Sc induces
neurodegeneration involves ER-stress, alterations in calcium
homeostasis and hyperactivation of CaN, a key brain phospha-
tase that controls important signaling events modulating
neuronal fate and functioning [49]. These findings indicate that
down regulation of CaN activity may be a promising target for
prion disease therapy. Fortunately, there are known CaN
inhibitors extensively studied, such as FK506 and Cyclosporin
[21]. FK506 is a FDA approved drug that is used to prevent
transplant regression [20]. The drug is sold under the name of
Tacrolimus or Prograf. FK506 is produced by Streptomyces
tsukubaensis [50]. By inhibiting CaN, the drug suppresses both
humoral and cellular immune responses. As an FDA approved
drug, the pharmacological properties of the compound are very
well-known.
Our results show that administration of FK506 during the
symptomatic phase of the disease produced a significant delay of
the disease progression manifested as an improvement on
behavioral abnormalities and increase survival time compared to
controls treated with vehicle. The effect is not dependent on the
immunosupresant activity of FK506, since rapamycin (a drug with
similar immunosupressive effect, but not acting through CaN) [51]
did not produce any change on prion disease. Moreover,
administration of FK506 did not alter the pattern of brain
inflammation, suggesting that the beneficial effect of this
compound is not mediated by neuroimmune pathways. Treatment
with FK506 led to a significant increase of pCREB and pBAD
levels in the brain, which paralleled the decrease of CaN activity.
Importantly, we observed lower degree of neurodegeneration in
animals treated with the drug, which was revealed by a higher
number of neurons and a lower quantity of degenerating nerve
cells. These changes were not dependent on PrP
Sc formation, since
the protein accumulated in the brain to the same levels as in the
untreated mice.
Figure 6. Treatment with FK506 decreases prion-induced neuronal loss. The number of neurons in various brain areas of mice infected or
non-infected with prions and subjected to diverse treatments was evaluated by histological analysis using the Neu-N antibody, which specifically
recognizes neuronal cells. A, representative pictures of the thalamus region after staining with Neu-N (brown) and Hoesch (blue) to stain nucleus. We
focused on thalamus, because this is one of the brain areas most severely affected in RML-affected animals. B, to quantitatively assess the number of
neurons in different groups we randomly selected two different regions of thalamus in each animal and two investigators blinded to the treatment
counted the number of neurons using the image pro software. In prion infected animals we observed some abnormal immunoreactivity in the form
of elongated structures. We believe this staining represents degenerated nerve cells process or cellular debris. We did not consider these
immunoreactivities in the neuronal counting. Each value corresponds to the average and standard error (n=3 for rapamycin group, and n=4 for all
other groups). The data was statistically analyzed by One-way ANOVA followed by the Tukey’s Multiple comparison post-test. * P,0.05; ** P,0.01;
*** P,0.001.
doi:10.1371/journal.ppat.1001138.g006
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other brain diseases associated to protein misfolding also involves
ER-stress, changes on calcium homeostasis and CaN activation
[52–55]. Recent studies have shown an increase in calcineurin
signaling during the early clinical symptoms of Alzheimer’s disease
[56]. Strikingly, administration of FK506 to transgenic mice
models of Alzheimer’s disease restore memory deficits associated
to the accumulation of amyloid-beta oligomers [57,58] and
reduced long-term potentiation deficits produced by aggregated
amyloid-beta [59]. These findings indicate that CaN may play a
general role in neurodegenerative diseases and could serve as a
novel target for therapeutic intervention in these devastating
diseases.
Methods
Ethics statement
All animal experiments were approved by and conducted in
strict accordance with guidelines of the Animal Care and Use
Committee of the University of Texas Medical Branch in
Galveston and the University of Texas Health Science Center in
Houston and complied with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health.
FK506 preparation
FK506 was purchased as a powder from LC Laboratories.
Purity was .95%. F506 stock solution (0.5 mg/ml) was prepared
by dissolving the compound in saline (0.9% NaCl) containing
1.25% PEG40 Castor Oil (Spectrum) and 2% ethanol. FK506
stock solution was stored frozen. Rapamycin (LC Laboratories)
was prepared in the same conditions.
CaN activity assay
The phosphatase activity of CaN was measured using the
Calcineurin Cellular Activity Assay kit from Calbiochem as
previously described [57]. The brain homogenate were prepared
in the assay buffer and the residual phosphate was removed by
passing through a desalting column. A final concentration of 1ug/
ul of the homogenate was used for the enzyme assay in presence of
bovine calmodulin. The reaction mixture was incubated with a
final concentration of 150mM RII peptide (substrate) at 37uC for
20 min and reactions were terminated by the addition of 100 ml
malachite green reagent. Product formation was measured by
recording the absorbance at 635 nm.
Purification of PrP
C and PrP
Sc
As a source of PrP
C we used mouse PrP recombinantly
expressed in bacteria, purified and folded into the native structure
using a previously described protocol [60]. Briefly, the murine prnp
gene (coding residues 23–230) was PCR-amplified from mouse
blood, inserted in a vector and used to transform BL21-Star E. coli
cells (Invitrogen). For purification, cell pellets were thawed and
resuspended, cells were lysed by adding 0.5 mg/mL Lysozyme
and subsequently sonicated. The released inclusion bodies were
pelleted by centrifugation and solubilized in buffer containing
Figure 7. CaN inhibitor reduces neurodegeneration in prion affected animals. Nerve cell degeneration was studied by Fluoro-Jade staining
in thalamus sections and visualized by fluorescence microscopy. Panel A shows representative pictures from several animals (3 for rapamycin, 4 for
the other groups) and panel B shows the number of degenerating neurons in each group. The data was statistically analyzed by One-way ANOVA
followed by the Tukey’s Multiple comparison post-test. *** P,0.001.
doi:10.1371/journal.ppat.1001138.g007
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C was purified by
using Ni Sepharose 6 Fast Flow resin (GE Healthcare) in batch-
mode. Recombinant PrP
C was on-column refolded for 6 h and
eluted with 500 mM Imidazole. The main peak was collected and
quickly filtered to remove aggregates. The protein was confirmed
to be monomeric and folded by size exclusion chromatography,
Western blotting and Circular Dichroism.
PrP
Sc was purified from the brain of RML scrapie sick mice,
following a previously described protocol [11]. Briefly, brains were
homogenized in PBS and after a low speed centrifugation, samples
were mixed with 1 volume of 20% sarkosyl. Samples were
centrifuged at 100,0006g for 3 hr at 4uC. Supernatant was
discarded; pellets were resuspended, layered over a 20% sucrose
cushion and centrifuged for 3h at 4uC. The supernatant was
discarded and the pellet resuspended, sonicated and incubated
with PK (100 mg/ml) for 2 h at 37uC and shaking. The digested
sample was layered over PBS containing 20% Sarkosyl, 0.1% SB
3–14 and 10% NaCl and centrifuged for 1h 30 min at 100.0006g.
The final pellet was resuspended in 100 ml of PBS and sonicated.
The sample was stored at 280uC. Purity was .90% as analyzed
by silver staining and amino acid composition analysis.
Cell toxicity studies
N2A cells were cultured in DMEM supplemented with 10% fetal
calf serum and antibiotics (10’000U/ml Penicillin, 10mg/ml strepto-
mycin), at 37uC and 5% CO2. For cell viability analysis, cells were
grown in collagen IV coated 96-well plates for 24h in cell culture
medium containing 1% serum before addition of the agonist. Cell
viability was quantified using 3-(4,5-dimethylthazol-2-yl)-5-3-carbox-
ymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and phen-
azine methosulfate (PMS) according to the recommendations of the
supplier (Promega). Cell death was determined measuring the amount
of LDH released to the culture media using the Cytotox 96 LDH kit,
following the manufacturer specifications (Promega).
Determination of cytoplasmatic calcium
The changes in intracellular calcium levels were measured
20 minutes after adding the reagents using the Fluo-4 Direct
Calcium Assay kit (Invitrogen) in 96 well plate according to
manufacturer’s protocol.
Animal model of prion diseases
The infectious model of prion disease in mice is a very good
model for TSEs, since it reproduces many of the clinical,
neuropathological and biochemical aspects of the disease in
humans and other mammals [61]. Wild type C57Bl6 mice were
injected intraperitoneally (i.p.) with 100mlo fb r a i nh o m o g e n a t e
containing infectious prions (RML strain). Approximately 210
days after inoculation, animals begin to show signs of scrapie.
The disease onset was monitored weekly by visual inspection,
using the following scale [62]: 1, normal animal; 2, roughcoat on
limbs; 3, extensive roughcoat, hunckback, and visible motor
abnormalities; 4, urogenital lesions; and 5, terminal stage of the
disease in which the animal presented with cachexia and lies in
the cage with little movement. Usually animals die few days after
reaching stage 5. The period between the appearance of the first
disease symptoms and death range between 20–40 days without
treatment. Some of the animals were left to die to determine
survival time and others were sacrificed at the indicated time by
exposure to CO2 inhalation to assess brain alterations. After
animal sacrifice half of the brain was fixed for histological
analysis and the other half was kept frozen for biochemical
assays.
Animal treatment
Treatment with FK506, rapamycin or vehicle was started when
animals exhibit the first signs of prion disease (stage 1 in our scale).
Animals were injected intra-peritoneally with 0.12 mg of the drug
(5 mg/Kg) dissolved in 100 ml of the vehicle solution mentioned
above. Administration was done daily until animals die or were
sacrificed for experiments.
Animal behavioral studies
To evaluate if treatment with FK506 alters clinical signs we
performed Open field and rotarod tests. The Open field test
monitor exploratory behavior and locomotor activity. Animals
were placed in a corner of the field box and all activity during
various 20s intervals was recorded by a video camera mounted
above the open field and scored in real-time. We measured and
analyzed total distance, average speed, time spent in various parts
of the field, rearing activity and inactive time. Testing was carried
out in a temperature, noise and light controlled room. Rota-rod
test is used to measure the motor activity and coordination.
Animals were placed on the rotating rod with an accelerated speed
(initial velocity 5 RPM; acceleration of 3) and the total time spent
on the rod was measured. The animal falls from a high of about
6 inches into a plastic platform that automatically counts the time
spent in the rod.
PrP
Sc detection assay
The presence and quantity of PrP
Sc in brain homogenates of
sick animals was measured by a standard assay consisting of the
ability of the misfolded protein to resist proteolytic degradation.
Samples were incubated in the presence of proteinase K (50 mg/
ml) during 60 min with shaking at 37uC. The digestion was
stopped by adding electrophoresis sample buffer and protease-
resistant PrP was detected by western blotting, as previously
described [63]. Briefly, proteins were fractionated by sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE),
electroblotted onto nitrocellulose membrane and probed with
6D11 antibody at a 1:5,000 dilution. The immunoreactive bands
were visualized by enhanced chemoluminesence assay (Amer-
sham) and densitometric analysis done by using a UVP image
analysis system.
Detection of pCREB and pBAD
Frozen brain samples were homogenized in RIPA buffer
containing a cocktail of protease inhibitors and were sonicated
for 15 s, and then centrifuged at 20,000 g for 5 min. The
supernatants were collected and protein concentration measured
using BCA assay (Pierce). 50mg of protein extracts were subjected
to SDS-PAGE, and western blotting. The membrane was
immunoblotted with pBAD, pCREB (Cell signaling; 1:1000)
antibodies and the target proteins were subsequently detected
using horseradish-peroxidase conjugated anti-IgG secondary
antibodies (Amersham Biosciences; 1:2000). Then the membrane
was stripped and reblotted with BAD, CREB (cell signaling;
1:1000) to determine the total protein level. In all cases the
membrane was reprobed with b-actin (Cell signaling;1:5000) to
ensure equal protein loading. As before gels were densitometrically
analyzed by the UVp image analysis system.
Postmortem neuropathological analysis
Histological studies were done to assess the effect of the
treatment on brain damage. For this purpose half of the brain was
fixed in 10% formaldehyde solution, embedded in paraffin and cut
in sections using a microtome. Serial sections (8 mm thick) from
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degeneration, brain inflammation, neuronal degeneration and
neuronal loss. The following studies were done: a) Brain Vacuolation.
One of the neuropathological hallmarks of prion diseases is the
presence of spongiform degeneration in the brain. Vacuolation
was assayed by staining of the tissue with Hematoxilin and eosilin.
Then, the number of vacuoles was counted in cerebellum,
hippocampus, inferior culliculum, occipital cortex, frontal cortex
and thalamus of each animal, as described [62]. b) Brain
inflammation. Astrocytosis was assayed by immunohistochemistry
utilizing antibodies against Glial Fibrillary Acidic Protein (GFAP)
expressed in abundance in activated astrocytes, following a
previously described protocol [62]. Staining for activated microglia
was done with the AIF-1 antibody. AIF-1 is a 17 kDa interferon-
gamma inducible calcium binding protein, associated with chronic
inflammatory processes, which has been previously used to assess
microglial activation in CJD patients [64]. Digital images were
collected on a Leica Microscope fitted with an apotome for
optimal sectioning. To calculate the extent of astrocytosis and
microglial activation, six 206 sections of Cortex, Thalamus,
Hippocampus and Cerebellum were collected per animal and the
stained area compared to the total tissue area was determined
using the image analysis program Image J from NIH. c)
Neurodegeneration. To evaluate neuronal degeneration and death
we used Fluoro-JadeB staining to detect degenerative cells and
NeuN, a specific marker for neurons. The Fluoro-Jade B staining
was done following the protocol described by Liu et al [65].
Briefly, 8 mm sections were cut from paraffin embedded brains
and spread on microscope slides and allowed to air dry followed by
mounting on microscope slides and placed in 70% ethanol. The
sections were washed and oxidized by soaking in a solution of
0.06% KMnO4 for 15min. After washing, they were stained with
0.001% Fluoro-JadeB (MiliPore) in 0.1%acetic acid for 20min.
Slides were washed again and dried overnight at room
temperature. Digital images were collected on a Leica Microscope
fitted with an apotome for optimal sectioning. Six 206sections of
Cortex, Thalamus, Hipocampus and Cerebellum were collected
per animal. Fluoro-Jade B positive cells were counted from each
field. The number of total neurons was counted after staining with
the monoclonal anti-NeuN antibody (Chemicon) at 1/1000
dilution. NeuN is a specific neuronal marker for a DNA-binding
protein present in the nucleus of postmitotic neurons [28]. Brain
sections were mounted onto gelatin-coated coverslips and allowed
to air dry. Air dried sections were blocked and permeabilized in
0.1MPB with 0.3% TX-100 (Sigma) and 10% goat serum
(PBTGS) for 1 h. Following permeabilization, the mouse mono-
clonal anti-NeuN antibody (Chemicon International) was applied
at a 1:200 dilution and incubated overnight at room temperature.
After washing, the secondary antibody and Hoechst (Molecular
Probes) were applied for 1 h at room temperature followed by 3
consecutive washes. Slides were visualized under the microscope
by two different researchers blinded to the treatment who counted
the number of neurons in different brain areas.
Statistical analysis
For the in vitro studies of the effect of PrP
Sc on calcium, CaN
activity and cell death, the data was analyzed by one-way
ANOVA, followed by the Tukey’s Multiple Comparison post-test
to estimate the significance of the differences. The in vivo survival
study was assessed by the Log-rank (Mantel-cox) test. The effect of
treatment on the rotarod performance was evaluated by two-ways
ANOVA using time and treatment as the variables. The
behavioral study by open field test and the differences on CaN
activity in animals at different times post-inoculation were
evaluated by unpaired t-test (two-tailed). Finally, the effect of
treatment on the CaN activity, CREB phosphorylation, BAD
phosphorylation, astroglyosis, microglial activation, number of
neurons and degenerating cells was analyzed by one-way
ANOVA, followed by the Tukey’s Multiple Comparison post-test
to estimate the significance of the differences. All statistical analysis
was done with the GraphPad Prism, version 5.0 software.
Supporting Information
Figure S1 Spongiform degeneration in the brain of prion-
infected mice treated with FK506. The vacuolation extent and
distribution was evaluated after hematoxilin-eosin staining of fixed
section. The figure shows representative pictures of 3 brain areas
(cerebellum, medulla, hippocampus) of various animals analyzed
in the different groups.
Found at: doi:10.1371/journal.ppat.1001138.s001 (0.35 MB PDF)
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